Gilead is acquiring Arcellx for $7.8 billion up front three years after forging a partnership with the biotech around a cell therapy for multiple myeloma. On the latest BioCentury This Week podcast, BioCentury’s analysts assess what the deal does for the Foster City, Calif.-based biotech’s pipeline.
The analysts also discuss the case for using ctDNA as a surrogate endpoint for early cancer trials.
Turning to Washington, Steve Usdin offers his takeaways from last week’s PhRMA Forum, which focused on China and the Trump administration’s most favored nation (MFN) drug pricing policy, and on the lessons that can be drawn from FDA’s about-face on the recent vaccine application from Moderna.

View full story: https://www.biocentury.com/article/658516

#BiotechMA #MultipleMyeloma #ctDNA #DrugPricingPolicy #FDA

00:00 - Introduction
02:34 - Gilead's Arcellx Buy
11:14 - ctDNA Surrogate Endpoints
21:59 - PhRMA Forum Takeaways
29:19 - FDA Moderna U-turn

To submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected].

Reach us by sending a text